Immix Biopharma, Inc. announced that it has entered into a securities purchase agreement with certain accredited investors to issue 3,831,216 common shares at an issue price of $2.37 and non-transferable warrants to purchase 2,873,417 shares of common stock for gross proceeds of $9,079,981.92, before deducting fees and expenses payable on September 5, 2025. The non-transferable warrants are exercisable over a ten-year period at an exercise price of $2 per share. The warrant will be exercisable on on September 5, 2035.
The company and the investors are executing and delivering this agreement in reliance upon the exemption from securities registration afforded by section 4(a)(2) of the securities act and rule 506 of Regulation D promulgated under the securities act.
